NCT00097903View on ClinicalTrials.gov

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

October 31, 2011

Study Completion Date

May 31, 2013

Conditions
CarcinomaCarcinoma, Non-Small-Cell Lung
Interventions
DRUG

Karenitecin (BNP1350)

Phase 1 study,dose-escalation design

Trial Locations (1)

65203

Ellis Fischel Cancer Center, Columbia

Sponsors

Collaborators (1)

Crown Bioscience
All Listed Sponsors
collaborator

Crown Bioscience

INDUSTRY

lead

BioNumerik Pharmaceuticals, Inc.

INDUSTRY

NCT00097903 - Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer | Biotech Hunter | Biotech Hunter